LS Investment Advisors LLC Lowers Stake in Hologic, Inc. (HOLX)

LS Investment Advisors LLC decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 26.0% in the 4th quarter, HoldingsChannel reports. The fund owned 11,965 shares of the medical equipment provider’s stock after selling 4,198 shares during the quarter. LS Investment Advisors LLC’s holdings in Hologic were worth $492,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Essex Savings Bank acquired a new stake in Hologic in the 4th quarter worth about $37,000. Creative Planning raised its stake in Hologic by 10.2% in the 4th quarter. Creative Planning now owns 16,736 shares of the medical equipment provider’s stock worth $688,000 after purchasing an additional 1,546 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in Hologic in the 4th quarter worth about $207,000. Advisors Asset Management Inc. raised its stake in Hologic by 90.4% in the 4th quarter. Advisors Asset Management Inc. now owns 24,535 shares of the medical equipment provider’s stock worth $1,008,000 after purchasing an additional 11,647 shares in the last quarter. Finally, Cordatus Wealth Management LLC acquired a new stake in Hologic in the 4th quarter worth about $1,628,000. 90.43% of the stock is owned by institutional investors.

HOLX has been the subject of several analyst reports. Canaccord Genuity reiterated a “hold” rating and issued a $41.00 price objective on shares of Hologic in a research note on Monday, January 7th. BidaskClub upgraded shares of Hologic from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 21st. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a research report on Monday, February 4th. Piper Jaffray Companies boosted their target price on shares of Hologic to $49.00 and gave the company an “overweight” rating in a research report on Thursday, January 31st. Finally, Morgan Stanley cut shares of Hologic from an “equal weight” rating to an “underweight” rating and dropped their target price for the company from $44.00 to $39.00 in a research report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $44.27.

Shares of NASDAQ:HOLX opened at $43.79 on Tuesday. The company has a market capitalization of $12.70 billion, a PE ratio of 19.64, a PEG ratio of 2.05 and a beta of 0.73. The company has a quick ratio of 0.91, a current ratio of 1.30 and a debt-to-equity ratio of 1.18. Hologic, Inc. has a 12 month low of $35.10 and a 12 month high of $45.45.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.01. The company had revenue of $830.70 million for the quarter, compared to analyst estimates of $823.22 million. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 EPS. As a group, research analysts expect that Hologic, Inc. will post 2.41 EPS for the current year.

In related news, insider Benjamin Jordan Cohn sold 10,000 shares of Hologic stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $44.49, for a total transaction of $444,900.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Allison P. Bebo sold 6,500 shares of Hologic stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $42.00, for a total transaction of $273,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 34,497 shares of company stock worth $1,507,865 over the last ninety days. 0.90% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2019/02/12/ls-investment-advisors-llc-lowers-stake-in-hologic-inc-holx.html.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply